Association of Homocysteine with Type 2 Diabetes: a Meta-analysis Implementing Mendelian Randomization Approach

Overview

Journal BMC Genomics

Publisher Biomed Central

Specialty Genetics

Date 2013 Dec 11

PMID 24320691

Citations 67

Authors

Tao Huang

Jingjing Ren

Jinyan Huang

Duo Li

Affiliations

Soon will be listed here.

Abstract

Background: We tested the hypothesis that elevated homocysteine (Hcy) level is causally associated with increased risk of type 2 diabetes mellitus (T2DM).

Results: The meta-analysis and Mendelian randomization analysis were performed among 4011 cases and 4303 controls. The absolute pooled mean Hcy concentration in subjects with MTHFR 677TT was 5.55 μmol/L (95% CI, 1.33 to 9.77) greater than that in subjects with MTHFR 677CC in T2DM. Overall, the T allele of the MTHFR 677 C > T conferred a greater risk for T2DM [Random effect (RE) OR = 1.31(1.17-1.64), I² = 41.0%, p = 0.055]. The random effect (RE) pooled OR associated with T2DM for MTHFR 677TT relative to the 677CC was [RE OR = 1.38(1.18-1.62)]. The fixed-effect pooled OR of the association for the MTHFR 677 TT vs CT was 1.29 (95% CI, 1.09-1.51). MTHFR 677 TT showed a significantly higher risk for T2DM compared with MTHFR 677 CC + CT [Fixed effect (FE) OR = 1.32(1.14-1.54), I² = 0.0%, p = 0.686]. The absolute pooled mean Hcy concentration in individuals with T2DM was 0.94 μmol/L (95% CI, 0.40-1.48) greater than that in control subjects. The estimated causal OR associated with T2DM was 1.29 for 5 μmol/L increment in Hcy.

Conclusions: Our findings provided strong evidence on the causal association of Hcy level with the development of T2DM.

Citing Articles

Association of folate levels with all-cause and cause-specific mortality in patients with arthritis.

Wang J, Gao F, Liu C, Wang F Clin Rheumatol. 2025; 44(3):953-968.

PMID: 39853557 DOI: 10.1007/s10067-025-07337-8.

Impact of single nucleotide polymorphisms (SNPs) in antioxidant-enzyme genes on the concentrations of folate, homocysteine and glutathione in plasma from healthy subjects after folic acid supplementation - a randomized controlled crossover trial.

Mansoor M, Stea T, Slettan A, Perera E, Maddumage R, Kottahachchi D Genes Nutr. 2025; 20(1):1.

PMID: 39838297 PMC: 11752798. DOI: 10.1186/s12263-024-00761-6.

Association of homocysteine and uric acid with type 2 diabetes mellitus: a case-control study.

Yang X, Lan Q, Wang Q, Xue Y, Zhang J, Li X Sci Rep. 2025; 15(1):1914.

PMID: 39809836 PMC: 11733023. DOI: 10.1038/s41598-025-85812-7.

Hyperhomocysteinemia and Disease-Is 10 μmol/L a Suitable New Threshold Limit?.

Marroncini G, Martinelli S, Menchetti S, Bombardiere F, Martelli F Int J Mol Sci. 2024; 25(22).

PMID: 39596358 PMC: 11594664. DOI: 10.3390/ijms252212295.

Values of H-Type Hypertension in Patients with Large Vessel Occlusion.

Xie D, Wan J, Guo C, Yang J, Huang J, Peng Z Clin Interv Aging. 2024; 19:1907-1917.

PMID: 39588060 PMC: 11587790. DOI: 10.2147/CIA.S488000.

References

Tanaka T, Scheet P, Giusti B, Bandinelli S, Piras M, Usala G . Genome-wide association study of vitamin B6, vitamin B12, folate, and homocysteine blood concentrations. Am J Hum Genet. 2009; 84(4):477-82. PMC: 2667971. DOI: 10.1016/j.ajhg.2009.02.011. View

Higgins J, Thompson S . Quantifying heterogeneity in a meta-analysis. Stat Med. 2002; 21(11):1539-58. DOI: 10.1002/sim.1186. View

Ratnam S, Maclean K, Jacobs R, Brosnan M, Kraus J, Brosnan J . Hormonal regulation of cystathionine beta-synthase expression in liver. J Biol Chem. 2002; 277(45):42912-8. DOI: 10.1074/jbc.M206588200. View

Buysschaert M, Dramais A, Wallemacq P, Hermans M . Hyperhomocysteinemia in type 2 diabetes: relationship to macroangiopathy, nephropathy, and insulin resistance. Diabetes Care. 2000; 23(12):1816-22. DOI: 10.2337/diacare.23.12.1816. View

Folsom A, Nieto F, McGovern P, Tsai M, MALINOW M, Eckfeldt J . Prospective study of coronary heart disease incidence in relation to fasting total homocysteine, related genetic polymorphisms, and B vitamins: the Atherosclerosis Risk in Communities (ARIC) study. Circulation. 1998; 98(3):204-10. DOI: 10.1161/01.cir.98.3.204. View

Kluijtmans L, van den Heuvel L, Boers G, Frosst P, STEVENS E, van Oost B . Molecular genetic analysis in mild hyperhomocysteinemia: a common mutation in the methylenetetrahydrofolate reductase gene is a genetic risk factor for cardiovascular disease. Am J Hum Genet. 1996; 58(1):35-41. PMC: 1914961. View

Tavakkoly Bazzaz J, Shojapoor M, Nazem H, Amiri P, Fakhrzadeh H, Heshmat R . Methylenetetrahydrofolate reductase gene polymorphism in diabetes and obesity. Mol Biol Rep. 2009; 37(1):105-9. DOI: 10.1007/s11033-009-9545-z. View

Lander E . The new genomics: global views of biology. Science. 1996; 274(5287):536-9. DOI: 10.1126/science.274.5287.536. View

Tutuncu N, Erbas T, Alikasifoglu M, Tuncbilek E . Thermolabile methylenetetrahydrofolate reductase enzyme genotype is frequent in type 2 diabetic patients with normal fasting homocysteine levels. J Intern Med. 2005; 257(5):446-53. DOI: 10.1111/j.1365-2796.2005.01480.x. View

10.

Kark J, Selhub J, Bostom A, Adler B, Rosenberg I . Plasma homocysteine and all-cause mortality in diabetes. Lancet. 1999; 353(9168):1936-7. DOI: 10.1016/s0140-6736(98)05381-1. View

11.

Yilmaz H, Agachan B, Ergen A, Karaalib Z, Isbir T . Methylene tetrahydrofolate reductase C677T mutation and left ventricular hypertrophy in Turkish patients with type II diabetes mellitus. J Biochem Mol Biol. 2004; 37(2):234-8. DOI: 10.5483/bmbrep.2004.37.2.234. View

12.

Bluthner M, Bruntgens A, Schmidt S, Strojek K, Grzeszczak W, Ritz E . Association of methylenetetrahydrofolate reductase gene polymorphism and diabetic nephropathy in type 2 diabetes?. Nephrol Dial Transplant. 1999; 14(1):56-7. DOI: 10.1093/ndt/14.1.56. View

13.

Hoogeveen E, Kostense P, Jakobs C, Dekker J, Nijpels G, Heine R . Hyperhomocysteinemia increases risk of death, especially in type 2 diabetes : 5-year follow-up of the Hoorn Study. Circulation. 2000; 101(13):1506-11. DOI: 10.1161/01.cir.101.13.1506. View

14.

Huang T, Tucker K, Lee Y, Crott J, Parnell L, Shen J . Methylenetetrahydrofolate reductase variants associated with hypertension and cardiovascular disease interact with dietary polyunsaturated fatty acids to modulate plasma homocysteine in puerto rican adults. J Nutr. 2011; 141(4):654-9. PMC: 3056580. DOI: 10.3945/jn.110.134353. View

15.

Hemati T, Moghadami-Tabrizi N, Davari-Tanha F, Salmanian B, Javadian P . High plasma homocysteine and insulin resistance in patients with polycystic ovarian syndrome. Iran J Reprod Med. 2015; 9(3):223-8. PMC: 4575758. View

16.

Meigs J, Jacques P, Selhub J, Singer D, Nathan D, Rifai N . Fasting plasma homocysteine levels in the insulin resistance syndrome: the Framingham offspring study. Diabetes Care. 2001; 24(8):1403-10. DOI: 10.2337/diacare.24.8.1403. View

17.

Song Y, Cook N, Albert C, Van Denburgh M, Manson J . Effect of homocysteine-lowering treatment with folic Acid and B vitamins on risk of type 2 diabetes in women: a randomized, controlled trial. Diabetes. 2009; 58(8):1921-8. PMC: 2712772. DOI: 10.2337/db09-0087. View

18.

Jacques P, Bostom A, Williams R, Ellison R, Eckfeldt J, Rosenberg I . Relation between folate status, a common mutation in methylenetetrahydrofolate reductase, and plasma homocysteine concentrations. Circulation. 1996; 93(1):7-9. DOI: 10.1161/01.cir.93.1.7. View

19.

Mehri S, Koubaa N, Nakbi A, Hammami S, Chaaba R, Mahjoub S . Relationship between genetic polymorphisms of angiotensin-converting enzyme and methylenetetrahydrofolate reductase as risk factors for type 2 diabetes in Tunisian patients. Clin Biochem. 2009; 43(3):259-66. DOI: 10.1016/j.clinbiochem.2009.10.008. View

20.

Smulders Y, Rakic M, Slaats E, Treskes M, Sijbrands E, Odekerken D . Fasting and post-methionine homocysteine levels in NIDDM. Determinants and correlations with retinopathy, albuminuria, and cardiovascular disease. Diabetes Care. 1999; 22(1):125-32. DOI: 10.2337/diacare.22.1.125. View